Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CureVac NV
Coronavirus Notebook: EMA Begins Rolling Review of Sinovac Vaccine, Looks At Comirnaty In 12-15-Year Age Group
Moderna and Sweden are donating vaccines to the COVAX Facility, and an African trial is investigating a combination of nitazoxanide and ciclesonide in people with mild-to-moderate COVID-19.
Coronavirus Notebook: 1.2bn Vaccines Produced Worldwide, ROVI To Double Moderna Capacity, Valneva starts UK Phase II/III trial
The World Health Organization has updated progress with evaluations of two Chinese vaccines and Russia's Sputnik V, the UK has ordered 60 million more Pfizer/BioNTech doses, and the European Medicines Agency is looking at the use of baricitinib in COVID-19 patients requiring oxygen.
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
Coronavirus Notebook: EU Launches Vaccine Monitoring Scheme, AZ Vows To Defend Itself Against Legal Action
The EMA has issued updated safety advice on AstraZeneca’s COVID-19 vaccine, Vaxzevria, Valneva has decided to pursue vaccine supply deals with individual member states after a falling out with the European Commission, and Kazakhstan has begun administering the first doses of its domestically produced vaccine, QazVac.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- CureVac GmbH
- CureVac BV